Sabatolimab

(Synonyms: MBG453)
目录号: PL06020
Sabatolimab (MBG453) 是一种高亲和力的人源化 IgG4 (S228P) 抗体,靶向 TIM-3,一种调节适应性和先天免疫反应的抑制性受体。Sabatolimab 是一种潜在的免疫抑制药物,可以靶向免疫细胞和骨髓细胞上的 TIM-3。
CAS No. :2252262-24-9
中文名称
Sabatolimab
英文名称
Sabatolimab
英文别名
MBG 453
Cas No.
2252262-24-9
包装储存
Please store the product under the recommended conditions in the Certificate of Analysis.
详情描述
Sabatolimab (MBG453) 是一种高亲和力的人源化 IgG4 (S228P) 抗体,靶向 TIM-3,一种调节适应性和先天免疫反应的抑制性受体。Sabatolimab 是一种潜在的免疫抑制药物,可以靶向免疫细胞和骨髓细胞上的 TIM-3。
产品详情
Sabatolimab (MBG453) 是一种高亲和力的人源化 IgG4 (S228P) 抗体,靶向 TIM-3,一种调节适应性和先天免疫反应的抑制性受体。Sabatolimab 是一种潜在的免疫抑制药物,可以靶向免疫细胞和骨髓细胞上的 TIM-3。
生物活性
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells.
性状
Liquid
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Andrew M. Brunner, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. Blood (2020) 136 (Supplement 1): 1–2.
搜索质检报告(COA)
[1]. Andrew M. Brunner, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. Blood (2020) 136 (Supplement 1): 1–2.

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2